Target family: Voltage-gated calcium channels  (Ca<sub>V</sub>) (type: vgic)
Target: Ca<sub>v</sub>1.4

Ligand: BAYK 8644 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Effects of congenital stationary night blindness type 2 mutations R508Q and L1364H on Cav1.4 L-type Ca2+ channel function and expression.
Published in: J Neurochem

Ligand: BAYK 8644 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): The CACNA1F gene encodes an L-type calcium channel with unique biophysical properties and tissue distribution.
Published in: J Neurosci

Ligand: BAYK 8644 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Cav1.4alpha1 subunits can form slowly inactivating dihydropyridine-sensitive L-type Ca2+ channels lacking Ca2+-dependent inactivation.
Published in: J Neurosci

Ligand: BAYK 8644 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Functional characterization of the L-type Ca2+ channel Cav1.4alpha1 from mouse retina.
Published in: Invest Ophthalmol Vis Sci

Ligand: diltiazem (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1982)
Primary target: no
Median affinity: 4 pIC50
Reference (Journal): Functional characterization of the L-type Ca2+ channel Cav1.4alpha1 from mouse retina.
Published in: Invest Ophthalmol Vis Sci

Ligand: isradipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1990)
Primary target: no
Median affinity:  -
Reference (Journal): Cav1.4alpha1 subunits can form slowly inactivating dihydropyridine-sensitive L-type Ca2+ channels lacking Ca2+-dependent inactivation.
Published in: J Neurosci

Ligand: isradipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1990)
Primary target: no
Median affinity: 6.699999809265137 pIC50
Reference (Journal): Functional characterization of the L-type Ca2+ channel Cav1.4alpha1 from mouse retina.
Published in: Invest Ophthalmol Vis Sci

Ligand: L-(cis)-diltiazem (Synthetic organic)
Interaction type: Gating inhibitor
Action: None
Ligand approved: no
Median affinity: 4.1 pIC50
Reference (Journal): Functional characterization of the L-type Ca2+ channel Cav1.4alpha1 from mouse retina.
Published in: Invest Ophthalmol Vis Sci

Ligand: nifedipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: no
Median affinity: 6 pIC50
Reference (Journal): The CACNA1F gene encodes an L-type calcium channel with unique biophysical properties and tissue distribution.
Published in: J Neurosci

Ligand: nimodipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1988)
Primary target: no
Median affinity: 6 pIC50

Ligand: nitrendipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: yes
Primary target: no
Median affinity: 6 pIC50

Ligand: (-)-(S)-BayK8644 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.760000228881836 pEC50

Ligand: verapamil (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1981)
Primary target: no
Median affinity:  -
Reference (Journal): Functional characterization of the L-type Ca2+ channel Cav1.4alpha1 from mouse retina.
Published in: Invest Ophthalmol Vis Sci